Amisulpride augmentation for clozapine-refractory positive symptoms: additional benefit in reducing hypersialorrhea.

Fabiani Bogorni,Frederico Fernandes Moreira,Géder Evandro Motta Grohs,Eduardo Mylius Pimentel,Alexandre Paim Diaz

doi:10.1155/2015/408179

Abstract

One-third to half of patients taking clozapine suffer from refractory symptoms despite adequate treatment. Among other adverse effects, clozapine-induced hypersalivation (CIH) occurs in approximately half of all patients. This is a case of a 30-year-old male with refractory schizophrenia; in this patient, the remission of residual positive symptoms, as well as the reduction of CIH, was achieved by treatment with clozapine augmented with amisulpride.

Highlights

30% of patients diagnosed with schizophrenia are resistant to antipsychotics and are candidates for treatment with clozapine
We report the case of a 30-year-old male with refractory schizophrenia; in this patient, the remission of residual positive symptoms, as well as the reduction of clozapineinduced hypersalivation (CIH), was achieved by treatment with clozapine augmented with amisulpride
Kreinin et al (2006) found a considerable reduction in CIH following amisulpride augmentation, in addition to significant improvements in negative symptoms [8]

Summary

Introduction

30% of patients diagnosed with schizophrenia are resistant to antipsychotics and are candidates for treatment with clozapine. One-third to half of patients taking clozapine suffer from refractory symptoms despite adequate treatment [1, 2]. Among other adverse effects, clozapineinduced hypersalivation (CIH) occurs in approximately half of all patients [3, 4]. We report the case of a 30-year-old male with refractory schizophrenia; in this patient, the remission of residual positive symptoms, as well as the reduction of CIH, was achieved by treatment with clozapine augmented with amisulpride

Case Report

Findings

Discussion